NCT02190695View on ClinicalTrials.gov

Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS

PHASE2CompletedINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

April 1, 2013

Primary Completion Date

June 26, 2018

Study Completion Date

April 16, 2020

Conditions
Acute Myeloid LeukemiaMyelodysplastic SyndromeChronic Myelomonocytic Leukemia
Interventions
DRUG

Decitabine

20 mg/m2 by vein daily over 1 hour on Days 1-5 of each 28 day cycle.

DRUG

Carboplatin

AUC 5 by vein over 1 hour on Day 8 of each 28 day cycle.

DRUG

Arsenic trioxide

0.15 mg/kg by vein over 1 hour on Days 1-5 of each 28 day cycle.

Trial Locations (2)

19111

Temple BMT Program at Jeanes Hospital, Philadelphia

77030

M.D. Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

M.D. Anderson Cancer Center

OTHER

collaborator

Teva Pharmaceuticals USA

INDUSTRY

lead

Fox Chase Cancer Center

OTHER

NCT02190695 - Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS | Biotech Hunter | Biotech Hunter